Desde:
24/03/2020
OFF:
3 Hor
"PharmaMar presentará la solicitud de autorización de comercialización (MAA) a la EMA en el primer semestre de 2025 para solicitar la aprobación en la Unión Europea"
0
Mensaje de: VpBroker Hora: 15/10/2024 14:00:43
Pero falta conocer los datos para saber si darán para presentar la aporbación acelerada no?
Pero falta conocer los datos para saber si darán para presentar la aporbación acelerada no?
"We are pleased with these clinically meaningful results and plan to submit an sNDA in the first half of 2025 to support this combination in the first-line maintenance setting.
2
https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-statistically-significant-overall
"We are pleased with these clinically meaningful results and plan to submit an sNDA in the first half of 2025 to support this combination in the first-line maintenance setting.5,0
(2)
0